Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021

Turpin, Anthony; El Amrani, Mehdi; Bachet, Jean-Baptiste; Pietrasz, Daniel; Schwarz, Lilian; Hammel, Pascal

Document type :

Compte-rendu et recension critique d'ouvrage

DOI :

10.3390/cancers12123866

PMID :

33371464

Permalink :

http://hdl.handle.net/20.500.12210/108095

Title :

Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021

Author(s) :

Turpin, Anthony [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service d'oncologie médicale (CHRU Lille)
El Amrani, Mehdi [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bachet, Jean-Baptiste [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
CHU Pitié-Salpêtrière [AP-HP]
Pietrasz, Daniel [Auteur]
Hôpital Paul Brousse
Schwarz, Lilian [Auteur]
CHU Rouen
Hammel, Pascal [Auteur correspondant]
Hôpital Paul Brousse

Journal title :

Cancers

Pages :

3866

Publisher :

MDPI

Publication date :

2020-12-21

ISSN :

2072-6694

English keyword(s) :

adjuvant therapy
biomarkers
neoadjuvant therapy
pancreatic cancer
precision medicine
timing

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Adjuvant chemotherapy is currently used in all patients with resected pancreatic cancer who are able to begin treatment within 3 months after surgery. Since the recent publication of the PRODIGE 24 trial results, modified ...
Show more >Adjuvant chemotherapy is currently used in all patients with resected pancreatic cancer who are able to begin treatment within 3 months after surgery. Since the recent publication of the PRODIGE 24 trial results, modified FOLFIRINOX has become the standard-of-care in the non-Asian population with localized pancreatic adenocarcinoma following surgery. Nevertheless, there is still a risk of toxicity, and feasibility may be limited in heavily pre-treated patients. In more frail patients, gemcitabine-based chemotherapy remains a suitable option, for example gemcitabine or 5FU in monotherapy. In Asia, although S1-based chemotherapy is the standard of care it is not readily available outside Asia and data are lacking in non-Asiatic patients. In patients in whom resection is not initially possible, intensified schemes such as FOLFIRINOX or gemcitabine-nabpaclitaxel have been confirmed as options to enhance the response rate and resectability, promoting research in adjuvant therapy. In particular, should oncologists prescribe adjuvant treatment after a long sequence of chemotherapy +/- chemoradiotherapy and surgery? Should oncologists consider the response rate, the R0 resection rate alone, or the initial chemotherapy regimen? And finally, should they take into consideration the duration of the entire sequence, or the presence of limited toxicities of induction treatment? The aim of this review is to summarize adjuvant management of resected pancreatic cancer and to raise current and future concerns, especially the need for biomarkers and the best holistic care for patients.Show less >

Language :

Anglais

Popular science :

Non

Collections :

Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL

Submission date :

2024-02-17T04:27:06Z

Files

document
Open access
Access the document

cancers-12-03866-v2.pdf
Open access
Access the document

Adjuvant Pancreatic Cancer Management: ... BibTeX CSV Excel RIS

Files

Adjuvant Pancreatic Cancer Management: ...

BibTeX

CSV

Excel

RIS